DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase  3 studies (SAKURA 1 and SAKURA 2)

DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A in clinical development. Phase 2 data have shown it offers a more prolonged duration of response than onabotulinumtoxinA.

Source: Journal of the American Academy of Dermatology - November 28, 2019 Category: Dermatology Authors: Vince Bertucci, Nowell Solish, Joely Kaufman-Janette, Steve Yoelin, Ava Shamban, Joel Schlessinger, Daniel Snyder, Conor Gallagher, Yan Liu, Gill Shears, Roman G. Rubio Tags: Original article Source Type: research